Intestinal Behçet's disease: A review of clinical diagnosis and treatment

Behçet's disease(BD)is a chronic inflammatory disorder prone to frequent re-currences,with a high predilection for intestinal involvement.However,the ef-ficacy and long-term effects of surgical treatment for intestinal BD are unknown.In the current issue of World J Gastrointest Surg,Park et al conducted a retrospec-tive analysis of 31 patients with intestinal BD who received surgical treatment.They found that elevated C-reactive protein levels and emergency surgery were poor prognostic factors for postoperative recurrence,emphasizing the adverse impact of severe inflammation on the prognosis of patients with intestinal BD.This work has clinical significance for evaluating the postoperative condition of intestinal BD.The editorial attempts to summarize the clinical diagnosis and treatment of intestinal BD,focusing on the impact of adverse factors on surgical outcomes.We hope this review will facilitate more precise postoperative management of patients with intestinal BD by clinicians.

Research Status of TCM Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD)

This paper mainly analyzes the application status of TCM rehabilitation in chronic obstructive pulmonary disease(COPD),hoping to provide support and help for clinical staff through this study,and promote the further development of COPD rehabilitation program.

Diagnosis and treatment of an elderly patient with 2019-nCoV pneumonia and acute exacerbation of chronic obstructive pulmonary disease in Gansu Province:A case report

BACKGROUND In December 2019,the first patient with 2019-novel coronavirus(2019-nCoV)was reported in Wuhan,China,and the disease spread rapidly across the country and surrounding countries within 2 mo.As of February 29,2020,a total of 91 confirmed cases had been reported in Gansu Province.This case report of the diagnosis and treatment of an elderly patient with 2019-nCoV pneumonia complicated by acute exacerbation of chronic obstructive pulmonary disease in Gansu Province aims to provide a better reference for the treatment of patients in the future.CASE SUMMARY The patient,a 94-year-old female,lived in Maiji District of Tianshui,Gansu Province,China.On January 30,2020,she was admitted to the Fourth People’s Hospital of Tianshui after 9 d of close contact with a patient with 2019-nCoV pneumonia.She was subsequently admitted to Gansu Provincial Hospital of Traditional Chinese Medicine for isolation and transferred to Tianshui Gansu Provincial Hospital of Infectious Diseases on February 3,2020 for treatment.Upon initial examination,her body temperature was 36.7°C,pulse was 80,breathing was 20,and blood pressure was 130/80 mmHg.She was conscious with normal development and normal nutrition.The pharynx was not red,and bilateral tonsils were not red and swollen.The lungs sounded slightly coarse with no dry or wet rales.The first symptoms were cough and fatigue on 2 February.The patient was hospitalized for 12 d.After active treatment,she was discharged on February 14 with a good prognosis.CONCLUSION A history of exposure to the affected area or patient is a major cause of 2019-nCoV infection,and population clustering is a high risk factor for transmission.Patients may not necessarily have respiratory system symptoms as the only clinical manifestation but may also have concomitant or first onset digestive symptoms.Attention should be paid to the prevention and treatment of multiple organ dysfunction syndrome.Nucleic acid testing is extremely important and needs to be repeated several times.Laboratory and auxiliary examination indicators during the first week of admission are extremely important.It is feasible to carry out dynamic and continuous index monitoring,which can predict and guide the prevention and treatment of multiple organ dysfunction and the prognosis of the disease.

Professor Chen Xianhai's experience of herb pairs in the treatment of pulmonary diseases

According to the theory of traditional Chinese medicine,based on the four properties and five flavors of traditional Chinese medicines,the lifting and lowering theory and channel tropism,Professor Chen combined with the theory of traditional Chinese medicine and constitution identification to prescribe for patients and used herb pairs to treat many kinds of pulmonary diseases.And he has achieved good clinical effect by"treatment methods selection according to syndromes".His experience in medication and compatibility mechanism are worthy of further exploration and promotion by scholars.

Treatment of patients with bosentan in postoperation of congenital heart disease with pulmonary arterial hypertension:a double-blind,randomized controlled trial

Objective Endothelin is a key role in the pathogenic of pulmonary arterial hypertension. High concentrations of endothelin 1 have been recorded in plasma and lungs of patients with pulmonary artery hypertension associated with congenital heart disease,and the concentrations of endothelin-1 was correlated with severity degree

Treatment with neurohormonal inhibitors and prognostic outcome in pulmonary arterial hypertension with risk factors for left heart disease

BACKGROUND Despite major advances in pharmacologic treatment,patients with pulmonary arterial hypertension(PAH)still have a considerably reduced life expectancy.In this context,chronic hyperactivity of the neurohormonal axis has been shown to be detrimental in PAH,thus providing novel insights on the role of neurohormonal blockade as a potential therapeutic target.AIM To evaluate the application and prognostic effect of neurohormonal inhibitors(NEUi)in a single-center sample of patients with idiopathic PAH and risk factors for left heart disease.METHODS We analyzed data retrospectively collected from our register of right heart catheterizations performed consecutively from January 1,2005 to October 31,2018.Patients on beta-blocker,angiotensin-converting enzyme inhibitor,angiotensin receptor blocker or mineralocorticoid receptor antagonist at the time of right heart catheterization were classified as NEUi users and compared to NEUi nonrecipients.RESULTS Complete data were available for 57 PAH subjects:27 of those(47.4%)were taking at least one NEUi at the time of right heart catheterization and were compared with the remaining 36 NEUi non-recipients.NEUi users were older and had a higher cardiovascular risk profile compared to non-recipients.Additionally,NEUi non-users had a higher probability of dying during the course of follow-up than NEUi recipients(56.7%vs 25.9%,log-rank P=0.020).CONCLUSION The above data highlighted a subgroup of patients with PAH and comorbidities for left heart disease in which NEUi use has shown to be associated with improved survival.Future prospective studies are needed to identify the most appropriate therapeutic strategies in this subset population.

Treat to target in Crohn’s disease:A practical guide for clinicians

A treat-to-target(T2T)approach applies the principles of early intervention and tight disease control to optimise long-term outcomes in Crohn's disease.The Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)-II guidelines specify short,intermediate,and long-term treatment goals,documenting specific treatment targets to be achieved at each of these timepoints.Scheduled appraisal of Crohn’s disease activity against pre-defined treatment targets at these timepoints remains central to determining whether current therapy should be continued or modified.Consensus treatment targets in Crohn’s disease comprise combination clinical and patient-reported outcome remission,in conjunction with biomarker normalisation and endoscopic healing.Although the STRIDE-II guidelines endorse the pursuit of endoscopic healing,clinicians must consider that this may not always be appropriate,acceptable,or achievable in all patients.This underscores the need to engage patients at the outset in an effort to personalise care and individualise treatment targets.The use of non-invasive biomarkers such as faecal calprotectin in conjunction with cross-sectional imaging techniques,particularly intestinal ultrasound,holds great promise;as do emerging treatment targets such as transmural healing.Two randomised clinical trials,namely,CALM and STARDUST,have evaluated the efficacy of a T2T approach in achieving endoscopic endpoints in patients with Crohn’s disease.Findings from these studies reflect that patient subgroups and Crohn’s disease characteristics likely to benefit most from a T2T approach,remain to be clarified.Moreover,outside of clinical trials,data pertaining to the real-world effectiveness of a T2T approach remains scare,highlighting the need for pragmatic real-world studies.Despite the obvious promise of a T2T approach,a lack of guidance to support its integration into real-world clinical practice has the potential to limit its uptake.This highlights the need to describe strategies,processes,and models of care capable of supporting the integration and execution of a T2T approach in real-world clinical practice.Hence,this review seeks to examine the current and emerging literature to provide clinicians with practical guidance on how to incorporate the principles of T2T into routine clinical practice for the management of Crohn’s disease.

Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study

AIM:To assesses the safety and efficacy of Aspergillus niger prolyl endoprotease(AN-PEP)to mitigate the im-munogenic effects of gluten in celiac patients.METHODS:Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet(GFD)resulting in normalised antibodies and mucosal healing classified as Marsh 0 orⅠwere included.In a randomised double-blind placebo-controlled pilot study,patients consumed toast(approximately 7 g/d gluten)with AN-PEP for 2 wk(safety phase).After a 2-wk washout period with adherence of the usual GFD,14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk(efficacy phase).Measurements at baseline included complaints,quality-of-life,serum antibodies,immunophenotyping of T-cells and duodenal mucosa immunohistology.Furthermore,serum and quality of life questionnaires were collected during and after the safety,washout and efficacy phase.Duodenal biopsies were collected after the safety phase and after the efficacy phase.A change in histological evaluation according to the modified Marsh classification was the primary endpoint.RESULTS:In total,16 adults were enrolled in the study.No serious adverse events occurred during the trial and no patients withdrew during the trial.The mean score for the gastrointestinal subcategory of the celiac disease quality(CDQ)was relatively high throughout the study,indicating that AN-PEP was well tolerated.In the efficacy phase,the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed.During the efficacy phase,neither the placebo nor the AN-PEP group developed significant antibody titers.The IgA-EM concentrations remained negative in both groups.Two patients were excluded from entering the efficacy phase as their mucosa showed an increase oftwo Marsh steps after the safety phase,yet with undetectable serum antibodies,while 14 patients were considered histologically stable on gluten with AN-PEP.Also after the efficacy phase,no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP.Furthermore,IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo.In the seven patients receiving AN-PEP,one patient showed increased and one showed decreased IgA-tTG deposits.CONCLUSION:AN-PEP appears to be well tolerated.However,the primary endpoint was not met due to lack of clinical deterioration upon placebo,impeding an effect of AN-PEP.

Early chronic obstructive pulmonary disease: Beyond spirometry

The significant healthcare burden associated with chronic obstructive pulmonary disease(COPD) is driving us to improve our understanding of the natural history of this disease. Historically, the focus has been largely centred on diagnosing and treating individuals with moderate and severe disease. However, it is now recognised that the speed of decline in lung function as measured by forced expiratory volume in 1 s occurs faster in the earlier stages of the disease process. As a result, a clearer understanding of the potential benefits of treatment in early COPD is needed. It is recognised that many patients with COPD remain undiagnosed in the community which has prompted global case-finding initiatives. In this review we discuss the difficulties in diagnosing COPD in its early stages, examine the roleof case-finding and look at the evidence for early intervention with therapeutic agents. There is a growing interest in the phenotypic variation amongst patients with COPD and we explore the role of phenotyping in early COPD and its potential benefits in providing a more individualised approach to COPD management. The majority of patients with COPD are known to die from non-respiratory causes such as cardiovascular disease. The mechanistic link is thought to relate to systemic inflammation, causing us to question whether earlier interventions could have a beneficial impact on the burden of co-morbidities for patients with COPD.

Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis

AIM To evaluate the efficacy of thalidomide for treating troublesome cases of pediatric Crohn's disease(CD) with tuberculosis infection.METHODS A retrospective study of clinical outcome among children treated with thalidomide was conducted. All patients had evidence of tuberculosis infection with a failure of anti-tuberculosis treatment for more than one year,and were subsequently diagnosed with CD. All the patients received thalidomide treatment with a starting dose of 1.2-2.5 mg/kg per day. Remission was defined as pediatric CD activity index less than or equal to 10.RESULTS Ten patients with CD were treated with thalidomide at an average age of 7.2 years and followed up for a median of 22.2 mo. Clinical remission rate was 60% after 9-12 mo of thalidomide treatment. One patient with no response had an interleukin-10 receptor alpha gene mutation. Erythrocyte sedimentation rate,C-reactive protein and platelet count showed a dramatic decrease; hemoglobin level and weight improved significantly after thalidomide treatment when compared with the baseline values.CONCLUSION Thalidomide is an effective and safe drug for remission of CD in pediatric patients who have been treated for tuberculosis.

The influence of intestine-based treatment using Xuan Bai Cheng Qi Tang on the concentration of trace elements in the main organs of COPD rats

Objective:To test two theories from traditional Chinese medicine:'exterior -interior relationship between the lung and large intestine' and 'treating from the intestine principle for lung disorders'.The influence of intestine-based treatment using Xuan Bai Cheng Qi Tang (XBCQT) on the concentration of three trace elements-copper (Cu),zinc (Zn),and manganese (Mn)-was observed in the tissues of the lung,small intestine,large intestine,and stomach of rats suffering from chronic obstructive pulmonary disease (COPD).Methods:Thirty-five male Wistar rats were divided randomly and equally into five groups:control;model;Fei treatment (A);Chang treatment (B);and Fei-Chang treatment (C).A rat model of COPD was prepared by tracheal injection of lipopolysaccharide plus exposure to cigarette smoke.Treatments with medicinal herbs started day-22 of administration and exposure to cigarette smoke for 7 days.The control group and model group were administered physiologic (0.9%) saline solution via the stomach.After 7 days of intervention,the tissues of the lung,small intestine,large intestine,and stomach were removed.Inductively coupled plasma-atomic emission spectroscopy was used to detect the levels of Cu,Zn,and Mn in those tissues.Results:Compared with the control group,the Cu concentration in the tissues of the small intestine,large intestine,and stomach increased significantly in the model group (P <.05);the Mn concentration in the tissues of the lung,large intestine,and stomach increased significantly in the model group (P <.05);the Zn concentration in the tissues of the lung and large intestine decreased significantly in the model group (P <.05).In comparison of the model group:the Cu concentration in the tissues of the lung and large intestine decreased significantly in the B group (P <.05);the Mn concentration in the tissues of the lung,small intestine,and large intestine decreased significantly in the B group (P <.05);the Zn concentration in the tissues of the lung,small intestine,and large intestine increased significantly in the B group (P <.05).For the A group versus C group comparison,the Zn concentration in the tissues of the small intestine and stomach increased significantly in the latter (P <.05).Conclusion:This study showed that 'treating from the intestine' using Xuan Bai Cheng Qi Tang and its modified formulae can regulate the concentration of trace elements in the main organs of COPD rats.This may be one of the mechanisms for intestine-based treatment for COPD.

Postoperative diarrhea in Crohn's disease:Pathogenesis,diagnosis,and therapy

Diarrhea is a frequent symptom in postoperative patients with Crohn’s diseases(CD),and several different mechanisms likely account for postoperative diarrhea in CD.A targeted strategy based on a comprehensive understanding of postoperative diarrhea is helpful for better postoperative recovery.

慢性阻塞性肺疾病合并骨质疏松的研究进展

慢性阻塞性肺疾病(COPD)以进行性、不完全可逆的气流受限为特征,是一种可预防和治疗的呼吸系统疾病。其合并症越来越受到重视,包括骨质疏松症、心脑血管疾病、代谢综合征、糖尿病、焦虑、抑郁等。其中骨质疏松症作为COPD的主要肺外合并症,严重威胁着患者的身心健康。COPD继发骨质疏松症的病因较多,包括缺氧状态、营养不良、体质量和运动能力下降、类固醇糖皮质激素应用、吸烟等。本文对COPD继发骨质疏松症的发病原因和治疗方法进行综述,试图为COPD继发骨质疏松症的预防与治疗提供理论依据。

王书臣教授辨证治疗肺痿经验

特发性肺间质纤维化(Idiopathic pulmonary fibrosis, IPF)已成为国际化难题,患者多病情进展迅速、生活质量低下、生存期短,单用西医激素和免疫抑制剂或细胞因子抑制剂治疗,难以延缓或逆转肺纤维化的进展,同时诸多药物反应限制其应用。通过中医辨证论治结合现代中药药理,王书臣教授对特发性肺间质纤维化的中医病名、病因病机及治疗原则形成了自己独特的见解,认为重症患者当以“肺痿”命名更佳,提出“治肺痿如治中风”“治肺痿当祛风”“治痿当兼顾脾胃”“肺肾同治”等观点,临床中用于患者治疗,疗效确切,为提高患者生活质量提供了宝贵经验。

中国儿童肺动脉高压诊治现状

肺动脉高压是一类具有不同的病因和发病特点、多因素致病的疾病。中国儿童肺动脉高压最常见的类型是先天性心脏病相关肺动脉高压和特发性肺动脉高压。现重点介绍这两类疾病的诊治现状,同时介绍与儿童肺动脉高压相关的其他疾病,以及分析当前存在的问题和挑战,并对未来进行展望。

物联网肺康复在慢性阻塞性肺疾病患者中的研究现状

慢性阻塞性肺疾病(COPD)是我国最常见的慢性呼吸系统疾病,患病率高,疾病负担重。提高COPD人群生存质量、延缓疾病进展、降低疾病负担是COPD的主要治疗目标。肺康复可提高患者的运动耐力、降低再住院率和死亡率、改善生活质量及致残率,是COPD重要的非药物治疗方式,也是COPD规范化治疗中的重要内容。肺康复在提升患者生活质量的同时,也实现了节约医疗资源,具有良好的经济和社会效益。但传统的居家肺康复模式存在患者不能全面掌握肺康复相关知识、容易遗忘、依从性较低等情况,导致患者出现肺康复积极性差、训练方式错误、训练强度过高或过低等诸多局限性。基于物联网的肺康复模式打破了地域限制,不仅为患者肺康复提供了安全保障、增加了康复的趣味性、提高了患者积极性及依从性,也有利于医生对患者肺康复情况的远程监测和指导,对COPD的诊疗、管理、改善预后、降低疾病负担等方面具有积极意义。

胸部定量CT对COPD患者治疗反应预测因素分析

目的分析胸部定量CT扫描对慢性阻塞性疾病(COPD)患者治疗反应的预测因素。方法回顾性分析2018年8月至2021年2月接受治疗COPD患者120例的临床资料,对其随访1年,根据肺功能检测结果将其分为有治疗反应组[n=24,第1秒用力呼气容积(FEV_(1))增加≥0.225 L]和非无治疗反应组(n=96,FEV_(1)增加<0.225 L)。对2组一般资料进行单因素分析,对其中差异有统计学意义的变量进行多因素Logistic回归分析,从而筛选出预测COPD患者治疗反应的因素。结果单因素分析结果显示,有治疗反应组和无治疗反应组在EI、ATI、Pi10、WA%、T方面的差异有统计学意义(P<0.05),而2组间性别比、年龄、体重指数、GOLD分期、入院肺功能检测的差异无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,Pi10为预测COPD患者治疗反应的因素(OR=2.321,P<0.05)。ROC曲线显示,Pi10在预测COPD患者治疗反应中具有极高的临床价值,ROC曲线显示,Pi10预测COPD患者治疗反应的曲线下面积为0.701,95%CI为0.610~0.781,约登指数为0.354,最佳截断值为4.65 mm,灵敏度为85.40%,特异度为50.00%。结论胸部定量CT扫描参数Pi10能够帮助预测COPD患者治疗反应。

基于态靶辨治理论诊疗慢性阻塞性肺疾病

慢性阻塞性肺疾病是常见的呼吸系统气道慢性病,严重影响患者的生活质量。传统的中医辨证论治体系存在对疾病的发生发展规律认识不足,对检查化验指标改善欠佳的问题。仝小林院士经过多年的临床实践,提出“态靶辨治”的现代中医诊疗体系,并将其用于慢性疾病临床诊疗过程中。基于此,以“态靶辨治”理论为指导,结合临床经验与现代药理学研究成果,将慢性阻塞性肺疾病发病过程分为“痰、阻、瘀、衰”四态(四期),每态下进行分证,并结合治疗靶点,确定各阶段相应的靶方靶药,构建慢性阻塞性肺疾病的态靶辨治体系,为提高该病的中医治疗效果提供新的路径。

肺肠同治理论下宣白承气汤结合肠内营养支持在慢性阻塞性肺疾病急性加重期治疗中的应用价值

【目的】探析肺肠同治理论指导下宣白承气汤结合肠内营养支持在慢性阻塞性肺疾病急性加重(AECOPD)治疗中的应用价值。【方法】将92例AECOPD肺热腑实型患者随机分为观察组和对照组,每组各46例。2组患者均给予常规对症治疗,在此基础上,对照组给予肠内营养支持干预,观察组给予宣白承气汤结合肠内营养支持干预,疗程为2周。观察2组患者治疗前后血清白蛋白(albumin,ALB)、前白蛋白(prealbumin,PA)、转铁蛋白(transferrin,TF)等营养指标及肠道菌群分布的变化情况,并比较2组患者的临床疗效及不良反应发生率。【结果】(1)疗效方面,治疗2周后,观察组的总有效率为97.83%(45/46),对照组为82.61%(38/46),组间比较(χ^(2)检验),观察组的疗效明显优于对照组,差异有统计学意义(P<0.05)。(2)营养指标方面,治疗后,2组患者的血清ALB、PA、TF水平均较治疗前明显升高(P<0.05),且观察组对血清ALB、PA、TF水平的升高幅度均明显优于对照组,差异均有统计学意义(P<0.05或P<0.01)。(3)肠道菌群分布方面,治疗后,2组患者的乳杆菌、双歧杆菌菌种数量均较治疗前明显升高(P<0.05),肠球菌菌种数量均较治疗前明显降低(P<0.05),且观察组对肠道乳杆菌、双歧杆菌菌种数量的升高幅度及对肠球菌菌种数量的降低幅度均明显优于对照组,差异均有统计学意义(P<0.05或P<0.01)。(4)不良反应方面,观察组的不良反应发生率为4.35%(2/46),明显低于对照组的19.57%(9/46),组间比较,差异有统计学意义(P<0.05)。【结论】肺肠同治理论指导下宣白承气汤结合肠内营养支持应用于AECOPD肺热腑实型患者临床效果显著,可有效改善患者营养状态及肠道菌群失衡,降低不良反应发生风险。

麻杏二三汤化裁联合常规西药治疗慢性阻塞性肺疾病急性加重期患者疗效及对气道炎症的影响

目的研究麻杏二三汤化裁联合常规西药治疗慢性阻塞性肺疾病(COPD)急性加重期患者疗效及对气道炎症的影响。方法选取浙江省绍兴市中医院2021年1月至2024年1月收治的80例COPD急性加重期患者,按照不同的治疗方法将其分为西药组(33例,采用常规西药治疗)和中西药结合组(47例,在西药组基础上加用麻杏二三汤化裁治疗),2组疗程均为10 d,对比2组患者治疗前后的临床疗效、肺功能状态、气道炎症及不良反应。结果中西药结合组临床有效率为(98%)高于西药组(79%)(χ^(2)=4.727,P<0.05);中西药结合组患者治疗后咳嗽、咳痰、呼吸不畅、喘息等证候评分分别为[(1.94±0.36)分、(1.32±0.43)分、(1.87±0.48)分、(1.85±0.37)分]均低于西药组[(2.36±0.43)分、(1.94±0.56)分、(2.13±0.41)分、(2.21±0.45)分](t=4.739、5.599、2.529、3.916,P均<0.05);治疗后,中西药结合组患者的动脉血氧分压(PaO_(2))和血氧饱和度(SaO_(2))分别为[(80.6±7.7)mmHg、(95.2±2.7)%]均高于西药组[(76.3±7.2)mmHg、(93.7±2.4)%](t=2.524、2.497,P均<0.05),二氧化碳分压(PaCO_(2))为(50±5)mmHg,低于西药组的(54±5)mmHg(t=3.192,P<0.05);治疗后,中西药结合组患者的肺活量(VC)、第1秒用力呼吸容积(FEV_(1))和呼吸峰值流速(PEF)分别为[(2.08±0.43)L、(1.81±0.20)L、(367±36)L/min]均高于西药组[(1.73±0.32)L、(1.65±0.24)L、(335±36)L/min](t=3.965、3.242、2.846,P均<0.05);治疗后,中西药结合组患者的C反应蛋白(CRP)、几丁质酶-3样蛋白1(CHI3L1)、缺氧诱导因子-1α(HIF-1α)、白细胞介素6(IL-6)和白介素10(IL-10)分别为[(22.3±2.2)mg/L、(41±4)μg/L、(60±15)μg/L、(4.4±1.0)ng/L、(4.5±1.2)pg/ml]均低于西药组[(32.4±2.7)mg/L、(49±4)μg/L、(80±16)μg/L、(5.4±1.4)ng/L、(6.3±1.4)pg/ml](t=18.545、8.985、2.991、4.351、6.134,P均<0.05),中西药结合组患者用药不良反应发生率(9%)与西药组(6.06%)对比差异无统计学意义(χ^(2)=0.168,P>0.05)。结论麻杏二三汤化裁联合常规西药治疗COPD急性加重患者的效果显著,能有效缓解患者症状,改善肺功能状态及气道炎症,安全性好,值得临床推广及应用。